DNAJB1-PRKACA peptide vaccine

Phase 1Vaccine

SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

DNAJB1-PRKACA peptide vaccine is one of 33 small molecule programs targeting Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver Cancer (fibrolamellar Hepatocellular Cancer (FLC))Not yet recruiting

Hepatocellular CarcinomaRecruiting

Liver Cancer (fibrolamellar Hepatocellular Cancer (FLC))Phase 1

Not yet recruiting

Hepatocellular CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Hepsera

Doptelet

1 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

Valemetostat

Bristol-Myers Squibb

Preclinical

1 8

Alcohol

Astellas

Preclinical

—9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

1 10

Targeted Therapy

FFudan University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1Not yet recruiting

Liver Cancer (fibrolamellar Hepatocellular Cancer (FLC))

NCT07430202

Q1 2034

Phase 1Recruiting

Hepatocellular Carcinoma

NCT04248569

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04248569·56 enrolled

Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))1 trial

A Phase 1b Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab for Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)

Not yet recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT07430202·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DNAJB1-PRKACA peptide vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DNAJB1-PRKACA peptide vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DNAJB1-PRKACA peptide vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

DNAJB1-PRKACA peptide vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q1 2034

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))1 trial

References

Drug Info

Quick Facts

Related News